M 021
Alternative Names: M-021Latest Information Update: 18 Jul 2025
At a glance
- Originator M6P Therapeutics
- Class Alpha-glucosidases; Enzymes; Recombinant proteins
- Mechanism of Action Alpha-glucosidase replacements; Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glycogen storage disease type II
Most Recent Events
- 18 Jul 2025 M6P Therapeutics plans to submit IND for Glycogen storage disease type II by third quarter of 2026 (M6P Therapeutics pipeline, July 2025)
- 18 Jul 2025 Pharmacodynamics data from a preclinical trial in Pompe disease released by M6P Therapeutics (M6P Therapeutics pipeline, July 2025)
- 09 Feb 2023 M 021 receives Rare pediatric drug status for Glycogen storage disease type II in USA prior to February 2023 (M6P Therapeutics website, February 2023)